Prospective Research Rare Kidney Stones (ProRKS)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Mayo Clinic
Study ID
NCT02780297
Status
Recruiting
Apply to this trial

Conditions

  • Adenine Phosphoribosyltransferase Deficiency
  • Cystinuria
  • Dent Disease
  • Hyperoxaluria
  • Lowe Syndrome

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

Key Dates

Start date
May 31, 2016
Status verified
Aug 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
220 participants (estimated)

Arms

  • Arm: Primary Hyperoxaluria Patients
    Patients with confirmed diagnosis of Primary Hyperoxaluria.
  • Arm: Dent Disease Patients
    Patients with confirmed diagnosis of Dent Disease.
  • Arm: Cystinuria Patients
    Patients with confirmed diagnosis of Cystinuria.
  • Arm: APRT deficiency Patients
    Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
  • Arm: Lowe Syndrome or Dent 2 patients
    Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
  • Arm: Dent 1 carriers
    Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
  • Arm: Enteric Hyperoxaluria Patients
    Patients with confirmed diagnosis enteric hyperoxaluria.

Primary Outcome Measure

inflammatory blood and urinary biomarkers [ Time Frame: Annually for 5 years ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
University of Alabama @ BirminghamBirminghamAlabama35294
Lisa Harvey
[email protected]
205-996-2613
Dean Assimos, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic JacksonvilleJacksonvilleFlorida32224
Arta Palaj
[email protected]
904-953-3071
Ivan Porter, MD
[email protected]
William Haley, MD (PRINCIPAL_INVESTIGATOR)
Children's Memorial HospitalChicagoIllinois60614
Heather Price, MS
[email protected]
Craig Langman, M.D. (PRINCIPAL_INVESTIGATOR)
Children's Hospital, Harvard Medical SchoolBostonMassachusetts02115
Leslie Spaneas
[email protected]
617-355-6129
Michael Somers, MD
[email protected]
Michelle Baum, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic Hyperoxaluria CenterRochesterMinnesota55905
Barb Seide
[email protected]
800-270-4637
Julie B Olson, RN
[email protected]
800-270-4637
Dawn Milliner, MD (PRINCIPAL_INVESTIGATOR)
New York UniversityNew YorkNew York10010
Frank Modersitzki, MPH
[email protected]
216-686-7500
Lada Beara-Lasic, MD
[email protected]
David Goldfarb, MD (PRINCIPAL_INVESTIGATOR)
Cincinnati Children's Hosptial Medical CenterCincinnatiOhio45229
Prasad Devarajan, MD
[email protected]
515-636-4200
Prasad Decarajan, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Taylor Moatz
[email protected]
267-425-3937
Lawrence Copelovitch, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By research site
University of Alabama @ Birmingham· Birmingham, ALMayo Clinic Jacksonville· Jacksonville, FLChildren's Memorial Hospital· Chicago, ILChildren's Hospital, Harvard Medical School· Boston, MAMayo Clinic Hyperoxaluria Center· Rochester, MNNew York University· New York, NY

Related Studies